Schedule 13G ownership disclosure
Protalix BioTherapeutics, Inc.
Security class unavailable · CUSIP: 74365A101
Event date: Unavailable
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 6,510,158
- Percent of class
- 6.9500%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001088875-15-000021
- Form type
- SC 13G
- Filer
- BAILLIE GIFFORD & CO
- CIK
- CIK 1088875
- Filed
- Jan 29, 2015
- Reporting period
- —
- Description
- Schedule 13G beneficial ownership